This article was originally published in The Tan Sheet
House Commerce/Oversight & Investigations Subcommittee scheduled to hold hearing March 11 on "date rape" drugs, including GHB and its precursor GBL. The subcommittee "will study whether the federal government is taking enough action to combat the use of date rape drugs." In a Jan. 21 "Talk Paper," FDA requested that seven manufacturers of GBL marketed as dietary supplements, including RenewTrient, voluntarily recall their products after numerous adverse reactions were reported ("The Tan Sheet" Jan. 25, p. 6). After the agency sent out four warning letters, all but one of the firms complied ("The Tan Sheet" Feb. 1, p. 3). The hearing is scheduled for 9:30 a.m
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC